ALX Oncology/ALXO

$15.96

1.4%
-
1D1W1MYTD1YMAX

About ALX Oncology

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a don’t eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. It focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. It also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.

Ticker

ALXO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jaume Pons

Employees

72

Headquarters

South san francisco, United States

ALX Oncology Metrics

BasicAdvanced
$806.45M
Market cap
-
P/E ratio
-$3.74
EPS
1.33
Beta
-
Dividend rate
$806.45M
1.32641
$17.42
$3.94
450.23K
5.24
5.909
6.293
-58.58%
-70.97%
-66.35%
4.234
4.251
-23.3%

What the Analysts think about ALX Oncology

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
26.25% upside
High $25.00
Low $14.00
$15.96
Current price
$20.15
Average price target

ALX Oncology Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-45.4M
-10.81%
Profit margin
0%
-

ALX Oncology Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 10.53%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.74
-$0.84
-$1.24
-$0.93
-
Expected
-$0.80
-$0.88
-$0.87
-$0.84
-$0.84
Surprise
-7.71%
-4.55%
42.53%
10.53%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for ALX Oncology stock?

ALX Oncology (ALXO) has a market cap of $806.45M as of April 19, 2024.

What is the P/E ratio for ALX Oncology stock?

The price to earnings (P/E) ratio for ALX Oncology (ALXO) stock is 0 as of April 19, 2024.

Does ALX Oncology stock pay dividends?

No, ALX Oncology (ALXO) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next ALX Oncology dividend payment date?

ALX Oncology (ALXO) stock does not pay dividends to its shareholders.

What is the beta indicator for ALX Oncology?

ALX Oncology (ALXO) has a beta rating of 1.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the ALX Oncology stock price target?

The target price for ALX Oncology (ALXO) stock is $20.15, which is 26.25% above the current price of $15.96. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell ALX Oncology stock

Buy or sell ALX Oncology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing